FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385185909> ?p ?o ?g. }

• W4385185909 endingPage "921" @default.
• W4385185909 startingPage "912" @default.
• W4385185909 abstract "Abstract Objective This dose-escalation part of an ongoing Phase I study assessed the tolerability, safety and pharmacokinetics of mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Methods Mosunetuzumab was administered intravenously, with step-up dosing in a 3 + 3 design, on Days 1, 8 and 15 of Cycle 1, and Day 1 of each subsequent 21-day cycle for up to 17 cycles to patients across five cohorts with different target doses (2.8, 6.0, 13.5, 27.0 or 60.0 mg). Results As of 5 July 2022, 23 patients had received mosunetuzumab. The median patient age was 63.0 years, 56.5% of patients were male, and 69.6% of patients had diffuse large B-cell lymphoma, 17.4% had transformed follicular lymphoma (FL) and 13.0% had FL. The median number of prior lines of therapy was 4. Mosunetuzumab was well tolerated and there were no deaths. The most common adverse events (any grade) were neutropenia/neutrophil count decreased (47.8%) and cytokine release syndrome (34.8%). Most cytokine release syndrome events were Grade 1/2 (one Grade 3), and most occurred within 24 hours of the first dose of mosunetuzumab. The apparent half-life of mosunetuzumab was 4.1–5.0 days. Two patients achieved a complete response, and 11 patients achieved a partial response. Conclusions This study demonstrated that mosunetuzumab has an acceptable safety profile and antitumor activity in Japanese patients with relapsed/refractory B-cell NHL. The recommended Phase II dose of 1.0/2.0/60.0/60.0/30.0 mg was tolerable and there were no new or different safety signals compared with the global Phase I study." @default.
• W4385185909 created "2023-07-25" @default.
• W4385185909 creator A5006679141 @default.
• W4385185909 creator A5027118202 @default.
• W4385185909 creator A5031782171 @default.
• W4385185909 creator A5044442609 @default.
• W4385185909 creator A5046638834 @default.
• W4385185909 creator A5055453369 @default.
• W4385185909 creator A5056191782 @default.
• W4385185909 creator A5056287200 @default.
• W4385185909 creator A5066865642 @default.
• W4385185909 creator A5081181665 @default.
• W4385185909 creator A5088100950 @default.
• W4385185909 creator A5090320088 @default.
• W4385185909 date "2023-07-22" @default.
• W4385185909 modified "2023-10-16" @default.
• W4385185909 title "Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma" @default.
• W4385185909 cites W1982589145 @default.
• W4385185909 cites W2058015212 @default.
• W4385185909 cites W2072351874 @default.
• W4385185909 cites W2082708772 @default.
• W4385185909 cites W2104173785 @default.
• W4385185909 cites W2133201432 @default.
• W4385185909 cites W2150587745 @default.
• W4385185909 cites W2406855906 @default.
• W4385185909 cites W2598700764 @default.
• W4385185909 cites W2744261860 @default.
• W4385185909 cites W2773804840 @default.
• W4385185909 cites W2897481316 @default.
• W4385185909 cites W2903062212 @default.
• W4385185909 cites W2905654445 @default.
• W4385185909 cites W2948510621 @default.
• W4385185909 cites W2948978639 @default.
• W4385185909 cites W3082855561 @default.
• W4385185909 cites W3095935882 @default.
• W4385185909 cites W3126684855 @default.
• W4385185909 cites W4200303223 @default.
• W4385185909 cites W4200488914 @default.
• W4385185909 cites W4200626931 @default.
• W4385185909 cites W4284987950 @default.
• W4385185909 cites W4285606063 @default.
• W4385185909 cites W4311537867 @default.
• W4385185909 doi "https://doi.org/10.1093/jjco/hyad082" @default.
• W4385185909 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37486002" @default.
• W4385185909 hasPublicationYear "2023" @default.
• W4385185909 type Work @default.
• W4385185909 citedByCount "0" @default.
• W4385185909 crossrefType "journal-article" @default.
• W4385185909 hasAuthorship W4385185909A5006679141 @default.
• W4385185909 hasAuthorship W4385185909A5027118202 @default.
• W4385185909 hasAuthorship W4385185909A5031782171 @default.
• W4385185909 hasAuthorship W4385185909A5044442609 @default.
• W4385185909 hasAuthorship W4385185909A5046638834 @default.
• W4385185909 hasAuthorship W4385185909A5055453369 @default.
• W4385185909 hasAuthorship W4385185909A5056191782 @default.
• W4385185909 hasAuthorship W4385185909A5056287200 @default.
• W4385185909 hasAuthorship W4385185909A5066865642 @default.
• W4385185909 hasAuthorship W4385185909A5081181665 @default.
• W4385185909 hasAuthorship W4385185909A5088100950 @default.
• W4385185909 hasAuthorship W4385185909A5090320088 @default.
• W4385185909 hasBestOaLocation W43851859091 @default.
• W4385185909 hasConcept C112705442 @default.
• W4385185909 hasConcept C121332964 @default.
• W4385185909 hasConcept C121608353 @default.
• W4385185909 hasConcept C126322002 @default.
• W4385185909 hasConcept C142424586 @default.
• W4385185909 hasConcept C197934379 @default.
• W4385185909 hasConcept C2777058707 @default.
• W4385185909 hasConcept C2777063308 @default.
• W4385185909 hasConcept C2777288759 @default.
• W4385185909 hasConcept C2777701055 @default.
• W4385185909 hasConcept C2778375690 @default.
• W4385185909 hasConcept C2778850193 @default.
• W4385185909 hasConcept C2779338263 @default.
• W4385185909 hasConcept C2780850621 @default.
• W4385185909 hasConcept C29730261 @default.
• W4385185909 hasConcept C3875195 @default.
• W4385185909 hasConcept C71924100 @default.
• W4385185909 hasConcept C87355193 @default.
• W4385185909 hasConcept C90924648 @default.
• W4385185909 hasConceptScore W4385185909C112705442 @default.
• W4385185909 hasConceptScore W4385185909C121332964 @default.
• W4385185909 hasConceptScore W4385185909C121608353 @default.
• W4385185909 hasConceptScore W4385185909C126322002 @default.
• W4385185909 hasConceptScore W4385185909C142424586 @default.
• W4385185909 hasConceptScore W4385185909C197934379 @default.
• W4385185909 hasConceptScore W4385185909C2777058707 @default.
• W4385185909 hasConceptScore W4385185909C2777063308 @default.
• W4385185909 hasConceptScore W4385185909C2777288759 @default.
• W4385185909 hasConceptScore W4385185909C2777701055 @default.
• W4385185909 hasConceptScore W4385185909C2778375690 @default.
• W4385185909 hasConceptScore W4385185909C2778850193 @default.
• W4385185909 hasConceptScore W4385185909C2779338263 @default.
• W4385185909 hasConceptScore W4385185909C2780850621 @default.
• W4385185909 hasConceptScore W4385185909C29730261 @default.
• W4385185909 hasConceptScore W4385185909C3875195 @default.
• W4385185909 hasConceptScore W4385185909C71924100 @default.
• W4385185909 hasConceptScore W4385185909C87355193 @default.

• next